Global Sexual Dysfunction Drugs Market 2017-2021

  • ID: 4392571
  • Report
  • Region: Global
  • 91 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Emotional Brain
  • Ivix LLX
  • Merck
  • Pfizer
  • MORE
About Sexual Dysfunction Drugs

Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market. Erectile dysfunction (ED) is a highly prevalent sexual dysfunction seen in men. Globally, there has been an increase in the number of ED cases caused due to high blood pressure, obesity, neurological and nerve disorders, prostate cancer, and diabetes among others.

The analysts forecast the global sexual dysfunction drugs market to grow at a CAGR of 2.79% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global sexual dysfunction drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Sexual Dysfunction Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Bayer
  • Eli Lilly
  • Pfizer
Other prominent vendors
  • Apricus Biosciences
  • Emotional Brain
  • GlaxoSmithKline
  • Ivix LLX
  • Leadiant Biosciences
  • Merck
  • NexMed
  • Palatin Technologies and PRA Health Sciences
  • S1 Biopharma
  • Takeda
  • Teva Pharmaceutical Industries
  • Trimel Biopharma SRL
  • Vietstar Biomedical Research
Market drivers
  • Rising prevalence of sexual dysfunctions
  • For a full, detailed list, view the full report
Market challenges
  • Technological advancements, a threat to drug therapy
  • For a full, detailed list, view the full report
Market trends
  • Increased focus on generic drugs
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Emotional Brain
  • Ivix LLX
  • Merck
  • Pfizer
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Disease overview
  • Sexual dysfunction: Definition
  • Causes of sexual dysfunction
PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Pipeline

PART 08: Market segmentation by therapy
  • Oral therapy
  • Intracavernosal therapy
  • Hormonal therapy
  • Transurethral therapy
PART 09: Geographical segmentation
  • Sexual dysfunction drugs market in Americas
  • Sexual dysfunction drugs market in EMEA
  • Sexual dysfunction drugs market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Increased focus on generic drugs
  • Migration of manufacturing and sales facilities to APAC
  • Advancing biomedical science
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • AbbVie
  • Bayer
  • Eli Lilly
  • Pfizer
  • Other prominent members
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Symptoms of sexual dysfunction in men and women
Exhibit 02: Types of sexual disorder
Exhibit 03: Causes of sexual dysfunction
Exhibit 04: Regional prevalence rate of ED June 2016
Exhibit 05: Global sexual dysfunction drugs market: Snapshot
Exhibit 06: Global sexual dysfunction drugs market 2016-2021 ($ millions)
Exhibit 07: Key drugs patent expiration in major countries
Exhibit 08: Opportunity analysis of global sexual dysfunction drugs market
Exhibit 09: Five forces analysis
Exhibit 10: Pipeline snapshot based on number of molecules 2016
Exhibit 11: Pipeline snapshot based on types of sexual dysfunction 2016
Exhibit 12: Key clinical trials
Exhibit 13: Global sexual dysfunction drugs market segmentation by therapy 2016
Exhibit 14: Oral therapies used as per drug class
Exhibit 15: Global sexual dysfunction oral drugs market 2016-2021 ($ millions)
Exhibit 16: Intracavernosal therapy used as per drug class
Exhibit 17: Global sexual dysfunction intracavernosal drugs market 2016-2021 ($ millions)
Exhibit 18: Some marketed intracavernosal drugs
Exhibit 19: Hormonal therapy used as per drug class
Exhibit 20: Global sexual dysfunction hormonal drugs market 2016-2021 ($ millions)
Exhibit 21: Transurethral therapy used as per drug class
Exhibit 22: Global sexual dysfunction transurethral drugs market 2016-2021 ($ millions)
Exhibit 23: Global sexual dysfunction drugs market share by geography 2016 and 2021
Exhibit 24: Global sexual dysfunction drugs market revenue by geography 2016-2021
Exhibit 25: Global sexual dysfunction drugs market share by geography 2016-2021
Exhibit 26: Snapshot of Global sexual dysfunction drugs market by geography 2016 and 2021
Exhibit 27: Market scenario in Americas
Exhibit 28: Sexual dysfunction drugs market in Americas 2016-2021 ($ millions)
Exhibit 29: Market scenario in EMEA
Exhibit 30: Sexual dysfunction drugs market in EMEA 2016-2021 ($ millions)
Exhibit 31: Market scenario in APAC
Exhibit 32: Sexual dysfunction drugs market in APAC 2016-2021 ($ millions)
Exhibit 33: Prevalence data of sexual dysfunction in women and men every year
Exhibit 34: Geriatric population analysis and estimates 2000 and 2030 (millions)
Exhibit 35: Mean number of prostate cancer diagnoses by five-year age band 2008-2010
Exhibit 36: Prevalence of ED in stroke patients 2008
Exhibit 37: Competitive structure analysis of global sexual dysfunction drugs market 2016
Exhibit 38: AbbVie: Key highlights
Exhibit 39: AbbVie: Strength assessment
Exhibit 40: AbbVie: Strategy assessment
Exhibit 41: AbbVie: Opportunity assessment
Exhibit 42: Bayer: Key highlights
Exhibit 43: Bayer: Strength assessment
Exhibit 44: Bayer: Strategy assessment
Exhibit 45: Bayer: Opportunity assessment
Exhibit 46: Eli Lilly: Key highlights
Exhibit 47: Eli Lilly: Strength assessment
Exhibit 48: Eli Lilly: Strategy assessment
Exhibit 49: Eli Lilly: Opportunity assessment
Exhibit 50: Pfizer: Key highlights
Exhibit 51: Pfizer: Strength assessment
Exhibit 52: Pfizer: Strategy assessment
Exhibit 53: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Emotional Brain
  • Ivix LLX
  • Merck
  • Pfizer
  • MORE
New Report Released: – Global Sexual Dysfunction Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global sexual dysfunction drugs market: AbbVie, Bayer, Eli Lilly, and Pfizer.

Other Prominent Vendors in the market are: Apricus Biosciences, Emotional Brain, GlaxoSmithKline, Ivix LLX, Leadiant Biosciences, Merck, NexMed, Palatin Technologies and PRA Health Sciences, S1 Biopharma, Takeda, Teva Pharmaceutical Industries, Trimel Biopharma SRL, and Vietstar Biomedical Research.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Increased focus on generic drugs. The global sexual dysfunction drugs market is currently witnessing an increasing focus of vendors toward the launch of generic drugs in the market. The patent expiration of many ED drugs has led to the entry of generics in the market. The cost-effective nature and the abundant availability of these drugs have led to the increase in the adoption rate of these drugs among physicians and end-users, thus adding to the market revenue.”

According to the report, one of the major drivers for this market is Rising prevalence of sexual dysfunctions. The global sexual dysfunction drugs market is currently witnessing an increasing prevalence rate of sexual dysfunction disorders in men and women. As per the NIH, the incidence rate of ED is 25-30 cases per thousand people per year globally, and this rate is directly proportional to age. A similar pattern is observed with women's sexual dysfunctions.

Further, the report states that one of the major factors hindering the growth of this market is Technological advancements, a threat to drug therapy. Many vendors in the market are innovating in terms of product technology to make ED solutions such as penile implants more reliable and natural-looking. For instance, Titan from Coloplast is made from Bioflex and silicone and is designed to imitate the appearance and mechanism of a natural erection. This will prompt more individuals to undergo penile implant surgeries to treat ED as these solutions provide a near-natural feel of penial erection.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AbbVie
  • Bayer
  • Eli Lilly
  • Pfizer
  • Apricus Biosciences
  • Emotional Brain
  • GlaxoSmithKline
  • Ivix LLX
  • Leadiant Biosciences
  • Merck
  • NexMed
  • Palatin Technologies and PRA Health Sciences
  • S1 Biopharma
  • Takeda
  • Teva Pharmaceutical Industries
  • Trimel Biopharma SRL
  • Vietstar Biomedical Research
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll